Trends in Drug Targeting for Cancer Treatment

References

• Akasaka Y., Ueda H., Takayama K., Machida Y., Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Delia 1988; 3: 85–97
   PubMedGoogle Scholar
• Aubree-Lecat A., Duban M. C., Demignot S., Domurado M. Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target. J. Pharmacokinet. Biopharmaceut. 1993; 21: 75–98
   PubMedGoogle Scholar
• Audus K. Brain uptake of drugs: The influence of chemical and biological factors. Adv. Drug Res. 1992; 23: 137–165
   Google Scholar
• Aukland K., Nicolaysen G. Interstitial fluid volume: Local regulatory mechanisms. Physiol. Rev. 1970; 61: 56–698
   Google Scholar
• Bakay L. The extracellular space in brain tumours. Brain 1970; 93: 693–699
   PubMedGoogle Scholar
• Baxter L., Jain R. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res. 1990; 40: 246–263
   PubMed Web of Science ®Google Scholar
• Begley D. Strategies for delivery of peptide drugs to the central nervous system: Exploiting molecule structure. J. Controlled Release 1994; 29: 293–306
   Web of Science ®Google Scholar
• Bennis S., Chapey C., Courver P., Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistance tumour cells in culture. Eur. J. Cancer 1994; 30A: 89–93
   PubMed Web of Science ®Google Scholar
• Better M., Weickman J. Engineering the bullet: Antibodies and bacteria. Chemtech May, 1993; 14–20
   Google Scholar
• Better M., Bernhard S. L., Lei S. P., Fishwild D. M., Lane J. A., Carrol S. F., Horwitz A. H. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2. Proc. Natl. Acad. Sci. USA 1993; 90: 457–461
   PubMed Web of Science ®Google Scholar
• Bischoff K. B., Dedrick R. L., Zaharko D. S., Longstreth J. A. Methotrexate pharmacokinetics. J. Pharmaceut. Sci. 1971; 60: 1128–1133
   PubMed Web of Science ®Google Scholar
• Blume G., Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta 1993; 1146: 157–168
   PubMed Web of Science ®Google Scholar
• Bock T. K., Müeller B. W. A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharmaceut. Res. 1994; 11: 589–591
   PubMed Web of Science ®Google Scholar
• Booser D. J., Hortobagyi G. N. Antracycline antibiotics in cancer therapy. Drugs 1994; 47: 223–258
   PubMed Web of Science ®Google Scholar
• Boucher Y., Baxter L., Jain R. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implication for therapy. Cancer Res. 1990; 50: 4478–4484
   PubMed Web of Science ®Google Scholar
• Breslow D. A polymer that fights cancer. Chemtech May, 1985; 302–307
   Google Scholar
• Broadwell R. D., Baker B. J., Ebert P. S., Hickey W. F. llografts of CNS tissue possess a blood-brain barrier. III. Neuropathological, methodological, and immunological considerations. Microsc. Res. Technol. 1994a; 27: 471–494
   PubMed Web of Science ®Google Scholar
• Casselas P., Bourie B. J., Gross P., Jansen F. K. Kinetics of cytoxicity induced by immunotoxins. Enhancement by lysomotropic amines and carboxylic ionophores. J. Biol. Chem. 1984; 259: 9359–9364
   PubMedGoogle Scholar
• Chappell M. J., Thomas G. D., Godfrey K. R., Bradwell A. R. Optimal tumor targeting by antibodies: Development of a mathematical model. J. Pharmacokinet. Biopharm. 1991; 19: 227–258
   PubMedGoogle Scholar
• Chen Y., McCulloch R., Gray B. Synthesis of albumin–dextran sulfate microspheres possessing favourable loading and release characteristics for the anticancer drug doxorubicin. J. Controlled Release 1994; 31: 49–54
   Web of Science ®Google Scholar
• Chikale E. G., Ng K. Y., Burton P. S., Borchard R. T. Hydrogen bonding potential as a determinant of the in vitro and in situ blood–brain barrier permeability of peptides. Pharmaceut. Res. 1994; 11: 412–419
   PubMed Web of Science ®Google Scholar
• Cohen J. Cancer vaccines get a shot in the arm. Science 1993; 262: 841–843
   PubMed Web of Science ®Google Scholar
• Colombatti M., Arciprete L. D., Chignola R., Tridente G. Carrier protein–monensin conjugates: Enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res. 1990; 50: 1385–1391
   PubMed Web of Science ®Google Scholar
• Comper W. D., Laurent T. C. Physiological function of connective tissue polysaccharides. Physiol. Rev. 1978; 58: 255–315
   PubMed Web of Science ®Google Scholar
• Covell D. G., Barbet J., Holton O. D., Black C. D. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab)2 and Fab in mice. Cancer Res. 1986; 46: 3969–3978
   PubMed Web of Science ®Google Scholar
• Dedrick R. nimal scale-up. J. Pharmacokinet. Biopharmaceut. 1973a; 1: 435–461
   PubMedGoogle Scholar
• Duncan R., Seymour L. W., O'Hare K. B., Flanagan P. A., Wedge S., Hume I. C., Ulrich K., Strohalm J., Subr V., Spreafico F., Grand M., Ripomonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release 1992; 19: 331–346
   Google Scholar
• Dunn S., Brindley A., Davis S., Davies M., Illum L. Polystyrenepoly(ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharmaceut. Res. 1994; 11: 1016–1022
   PubMed Web of Science ®Google Scholar
• Ekrami H., Kennedy A. R., Witschi H., Shen W. Cationized Bowman–Birk protease inhibitor as a targeted cancer chemopreventive agent. J. Drug Target. 1993; 1: 41–49
   PubMed Web of Science ®Google Scholar
• Eskey C. J., Wolmark N., McDowell C. L., Domach M. M., Jain R. K. Residence time distributions of various tracers in tumors: Implications for drug delivery and blood flow measurement. J. Natl. Cancer Inst. 1994; 86: 293–299
   PubMed Web of Science ®Google Scholar
• Friden P. M., Walus L. R., Musso G. F., Taylor M. A. Anti–transferrin receptor antibody and antibody–drug conjugates cross the blood–brain barrier. Proc. Natl. Acad. Sci. USA 1991; 88: 4771–4775
   PubMed Web of Science ®Google Scholar
• Fross R., Warnke P., Groothius D. Blood flow and blood-to-tissue transport in 9L gliosarcomas: The role of the brain tumor model in drug delivery research. J. Neurol. Oncol. 1991; 11: 185–197
   PubMed Web of Science ®Google Scholar
• Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J. Nucl. Med. 1990; 31: 1191–1198
   PubMed Web of Science ®Google Scholar
• Fujimori K., Fisher D., Weinstein J. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: The radiation dose distribution. Cancer Res. 1991; 51: 4821–4827
   PubMed Web of Science ®Google Scholar
• Gallo J. M., Gupta P. K., Hung C. T., Perrier D. G. Evaluation of the drug delivery following the administration of magnetic albumin microspheres containing Adriamycin to the rat. J. Pharm. Sci. 1989; 78: 190–194
   PubMed Web of Science ®Google Scholar
• Gallo J. M., Varkonyi P., Hassan E. E., Grothius D. R. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetics model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokinet. Biopharm. 1993; 21: 575–593
   PubMedGoogle Scholar
• Gelvan D., Samuni A. Reappraisal of the association between Adriamycin and iron. Cancer Res. 1988; 48: 5645–5649
   PubMed Web of Science ®Google Scholar
• Gerlowski L. E., Jain R. K. Physiologically based pharmacokinetics: Principles and applications. J. Pharm. Sci. 1983; 72: 1103–1127
   PubMed Web of Science ®Google Scholar
• Gibaud S., Andreux J. P., Weingarten C., Renard M., Couvreur P. Increased bone-marrow toxicity of doxorubicin bound to nanoparticles. Eur J. Cancer 1994; 30A: 820–826
   PubMed Web of Science ®Google Scholar
• Gipps E. M., Arshady R., Kreuter J., Groscurth P., Speiser P. P. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J. Pharmaceutical Sci. 1986; 75: 256–258
   PubMed Web of Science ®Google Scholar
• Grayson M. Cancer drugs in development. J. Natl. Cancer Inst. 1994; 86: 823–824
   Web of Science ®Google Scholar
• Gregoriadis G. Liposome Technology. CRC Press, Boca Raton, FL 1984; Vols. I–III
   Google Scholar
• Gregoriadis G., Florence A. T. Recent advances in drug targeting. Tibtech 1994; 11: 440–442
   Web of Science ®Google Scholar
• Griffin T. W., Morgan A. C., Blythman H. E. Immunotoxin therapy: Assessment by animals models. Immunotoxins, A. E. Frankel. Kluwer, New York 1988; 433–456
   Google Scholar
• Griffin T., Rybak M. E., Recht L., Singh S., Salami A., Raso V. Potentiation of antitumor immunotoxins by liposomal monensin. J. Natl. Cancer Inst. 1993; 85: 292–298
   PubMed Web of Science ®Google Scholar
• Gullino P. M. Extracellular compartments of solid tumors. Cancer Res. 1975; 3: 327–354
   Google Scholar
• Hamberg L. M., Kristjansen P. E., Hunter G. J., Wolf G. L., Jain R. K. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 μL resolution. Cancer Res. 1994; 54: 6032–6036
   PubMed Web of Science ®Google Scholar
• Harper G. R., Davies M. C., Davis S. S., Tadros T. F. Steric stabilisation of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cells in vitro. Biomaterials 1991; 12: 695–700
   PubMed Web of Science ®Google Scholar
• Hassan E. E., Gallo J. M. Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres. J. Drug Target. 1993; 1: 7–14
   PubMed Web of Science ®Google Scholar
• Hassan E. E., Parish R., Gallo J. M. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm. Res. 1992; 9: 390–397
   PubMed Web of Science ®Google Scholar
• Huang S. K., Stauffer P. R., Hong K., Guo J. W., Phillips T. L., Huang A., Papahadjopoulos D. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994; 54: 2186–2191
   PubMed Web of Science ®Google Scholar
• Huennekens F. M. Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugates. Tibtech 1994; 12: 234–242
   PubMed Web of Science ®Google Scholar
• Ishii F., Nagasaka Y., Ogata H. Interaction between erythrocytes from various animals and emulsions stabilized with various lecithins. J. Pharm. Sci. 1989; 78: 303–306
   PubMed Web of Science ®Google Scholar
• Iwate M., Machida Y., Nagai T. Double-layered stick-type formulation of bleomycin for treatment of uterine cervical cancer. Drug Des. Delia 1987; 1: 253
   PubMedGoogle Scholar
• Jain R. K. Mass transport in tumors: Characterization and applications to chemotherapy. Adv. Cancer Res. 1980; 33: 251–295
   PubMedGoogle Scholar
• Jain R. K. Mass and heat transfer in tumors. Adv. Transp. Process. 1984; 3: 205–339
   Google Scholar
• Jain R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987; 6: 559–593
   PubMed Web of Science ®Google Scholar
• Jain R. K. Transvascular and interstitial transport in tumors. Vascular Endothelium in Health and Disease, S. Chien. Elsevier, Amsterdam 1988a; 215–220
   Google Scholar
• Jain R. K. Determination of tumor blood flow: A review. Cancer Res. 1988b; 48: 2641–2658
   PubMed Web of Science ®Google Scholar
• Jain R. K. Physiological resistance to the treatment of solid tumors. Drug Resistance in Oncology, B. A. Teicher. Marcel Dekker, New York 1993; 87–105
   Google Scholar
• Jain R. K. Barriers to drug delivery in solid tumors. Sci. Am. 1994; 271(1)58–65
   PubMed Web of Science ®Google Scholar
• Jones C., Burton M., Gray B. lbumin microspheres as vehicles for the sustained and controlled release of doxorubicin. J. Pharm. Pharmacol. 1989a; 41: 813–816
   PubMed Web of Science ®Google Scholar
• Kang Y., Bickel U., Pardrige W. Pharmacokinetics and saturable blood–brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab. Dispos. 1994; 22: 99–105
   PubMed Web of Science ®Google Scholar
• Karte N., Knauf M., Laird W. Chemical modification of recombinant interleukin 2 by polyethylene glycol increase its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA 1987; 84: 1487–1491
   PubMed Web of Science ®Google Scholar
• Kataoka K., Kwon G. S., Yokoyama M., Okano T., Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J. Controlled Release 1993; 24: 119–132
   Web of Science ®Google Scholar
• Kim S. Liposomes as carriers of cancer chemotherapy. Drugs 1993; 46: 618–638
   PubMed Web of Science ®Google Scholar
• Kopecek J., Duncan R. Targetable polymeric drugs. J. Controlled Release 1987; 6: 315–327
   Google Scholar
• Kralovec J., Spencer G., Blair A. H., Mammen M., Singh M., Ghose T. Synthesis of methotrexate–antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities. J. Med. Chem. 1989; 32: 2426–2431
   PubMed Web of Science ®Google Scholar
• Kratz F., Hartmann M., Keppler B., Messori L. The binding properties of two antitumor ruthenium (III) complexes to apotransferrin. J. Biol. Chem. 1994; 269: 2581–2588
   PubMed Web of Science ®Google Scholar
• Kulkarni S. B., Betagiri G. V., Singh M. Factors affecting microencapsulation of drugs in liposomes. J. Microencapsul. 1995; 12: 229–246
   PubMed Web of Science ®Google Scholar
• Labib A., Lenaerts V., Chouinard F., Leroux J. C., Ouellet R., Van Lier J. E. Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm. Res. 1991; 8: 1027–1031
   PubMed Web of Science ®Google Scholar
• Langer R. New methods of drug delivery. Science 1990; 249: 1527–1533
   PubMed Web of Science ®Google Scholar
• Laurent T. C. Structure, function and tumover of the extracellular matrix. Adv. Microcirc. 1987; 13: 47–57
   Google Scholar
• Leon J. A., Goldstein N. I., Fisher P. B. New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer. Pharm. Ther. 1994; 61: 237–278
   PubMed Web of Science ®Google Scholar
• Leung H. S., Robinson J. R. Bioadhesive drug delivery in water-soluble polymers. Synthesis, solution properties, and applications. ACS Symp. Ser. 1991; 467: 350–363
   Google Scholar
• Levin V. A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980; 23: 682–684
   PubMed Web of Science ®Google Scholar
• Levin V. A. Fundamentals of Cancer Chemotherapy. McGraw-Hill, New York 1987; 32–33
   Google Scholar
• MacDougall J. D. B., McCabe M. Diffusion coefficient of oxygen through tissues. Nature 1967; 215: 1173–1174
   PubMed Web of Science ®Google Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 1991; 6: 181–202
   Web of Science ®Google Scholar
• Maeda H., Seymour L., Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 1992; 3: 351–362
   PubMed Web of Science ®Google Scholar
• Nucci M., Shorr R., Abuchowski A. The therapeutic values of poly(ethylene glycol)-modified proteins. Adv. Drug Delivery Rev. 1991; 6: 133–151
   Web of Science ®Google Scholar
• Nugent L. J., Jain R. K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res. 1984; 44: 238–244
   PubMed Web of Science ®Google Scholar
• Olsnes S., Sandvig K. How protein toxins enter and kill cells. Cancer Treat. Res. 1988; 37: 39–73
   PubMedGoogle Scholar
• Osdol V. W., Fujimori K., Weinstein J. n analysis of monoclonal antibody distribution in microscopic tumors nodules: Consequences of a “binding site barrier”. Cancer Res. 1991a; 51: 4776–4784
   PubMed Web of Science ®Google Scholar
• Ouchi T. Release behaviour of 5-fluorouracil from chitosan-gel microspheres modified chemically and their antitumor activities. Biotechnology and Bioactive Polymers, C. Gebelein, C. Carraher. Plenum Press, New York 1994; 289–296
   Google Scholar
• Papahadjopoulos D., Gabizon A. A. Liposomes as Tools in Basic Research and Industry, J. R. Philippot, F. Schuber. CRC Press, Boca Raton, FL 1995; 177–188
   Google Scholar
• Pardrigde W. M. Peptide Drug Delivery to the Brain. Raven Press, New York 1991; 108–118
   Google Scholar
• Pardrigde W. M. New approaches to drug delivery through the blood-brain barrier. Tibtech 1994; 12: 239–245
   PubMed Web of Science ®Google Scholar
• Pardrigde W. M., Kang Y. S., Buciak J. L. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 1994; 11: 738–746
   PubMed Web of Science ®Google Scholar
• Pass H. Photodynamic therapy in oncology: Mechanisms and clinical use. J. Natl. Cancer Inst. 1993; 85: 443–456
   PubMed Web of Science ®Google Scholar
• Pastan I., Fitzgerald D. Recombinant toxins for cancer treatment. Science 1991; 254: 1173–1177
   PubMed Web of Science ®Google Scholar
• Peltier N. W., Uhl J., Steel V., Brophy L., Liversidge E. M. Direct suppression of phagocytosis by amphiphilic polymeric surfactants. Pharm. Res. 1992; 9: 1177–1183
   PubMed Web of Science ®Google Scholar
• Raso V., Lawrence J. Carboxylic ionophores enhance the cytotoxic potency of ligand and antibody delivered ricin A chain. J. Exp. Med. 1984; 160: 1234–1240
   PubMed Web of Science ®Google Scholar
• Regelson W. International Encyclopedia of Pharmacy and Therapeutics, M. Mitchell. Pergamon Press, New York 1985; Vol. 115: 1–44
   Google Scholar
• Regelson W. Heparin, heparinoids, synthetic polyanions, and anionic dyes. ACS Symp. Set. 1991; 467: 368–372
   Google Scholar
• Ringsdorf H., Schmidt B. How to bridge the gap between membrane biology and polymer science. Synthetic Membranes: Science, Engineering and Applications, P. M. Bungay, et al. Reidel, Dordrecht 1986; 701–712
   Google Scholar
• Sandford P. A., Steinnes A. Biomedical applications of high-purity chitosan. ACS Symp. Ser. 1991; 467: 430–438
   Google Scholar
• Schinazi R. F., Goudgaon N. M., Fulcrand G., El Kattan Y. Cellular pharmacology and biological activity of 5-carboranyl-2′-deoxyuridine. Int. J. Radiat. Oncol. Biol. Phys. 1994; 28: 1113–1120
   PubMed Web of Science ®Google Scholar
• Schuerch C. Biomedical application of polysaccharides. Bioactive Polymeric Systems—An Overview, C. G. Gebelein, C. E. Carraher. Plenum Press, New York 1985; 383–384
   Google Scholar
• Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene-glycol)-coated vesicles. Biochim. Biophys. Acta 1991; 1062: 77–82
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Ulbrich K., Steyger P. S., Brereton M., Subr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based dosorubicin prodrugs in the treatment of subcutaneous murine B 16F10 melanoma. Brit. J. Cancer 1994; 70: 636–641
   PubMed Web of Science ®Google Scholar
• Silver P. J. Optimizing organization and effectiveness of pharmaceutical discovery by molecular target rather than by therapeutic area. Drug Dev. Res. 1994; 32: 1–5
   Web of Science ®Google Scholar
• Singh M., Faulkner G., Ghose T., Mezei M. ntibody directed targeting of methotrexate-containing small unilamellar vesicles. Cancer Immunol. Immunother. 1988a; 27: 17–25
   PubMed Web of Science ®Google Scholar
• Singh M., Kralovec J., Mezei M., Ghose T. Inhibition of human renal cancer by methotrexate linked to a monoclonal antibody. J. Urol. 1989; 141: 428–431
   PubMed Web of Science ®Google Scholar
• Singh M., Griffin T., Salami A., Micetich R. G., Atwal H. Potentiation of ricin A immunotoxin by monoclonal antibody targeted monesin containing small unilamellar vesicles. Cancer Lett. 1994; 84: 15–21
   PubMed Web of Science ®Google Scholar
• Singh M., Singh M. P., Ablordeppy S. In vitro studies with liposomal cryptolepine. Drug Dev. Ind. Pharm. 1996; 22: 379–383
   Google Scholar
• Smith R. A. G., Dewdney J. M., Fears R., Poste G. Chemical derivatization of therapeutic proteins. Tibtech 1993; 11: 397–403
   PubMed Web of Science ®Google Scholar
• Straubinger R. M., Sharma A., Mayhew E. Formulation and antitumor activity of taxol in liposomes. Proc. Am. Assoc. Cancer Res. 1994; 35: 404
   Google Scholar
• Sung C., Youle R., Dedrick R. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: Role of plasma kinetics, capillary, permeability, and binding. Cancer Res. 1990; 50: 7382–7392
   PubMed Web of Science ®Google Scholar
• Sung C., Shockley T. R., Morrison P. F., Dvorack H. F., Yarmush M. L., Dedrick R. L. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 1992; 52: 377–384
   PubMed Web of Science ®Google Scholar
• Sutherland R. Cell and environment interactions in tumor microregions: The multicell spheriod model. Science 1988; 240: 177–184
   PubMed Web of Science ®Google Scholar
• Suzuki H., Zelphati O., Hildebrand G., Lesemian L. CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes. Exp. Cell Res. 1991; 193: 112–119
   PubMed Web of Science ®Google Scholar
• Swabb E. A., Wei J., Gullino P. M. Diffusion and convection in normal and neoplastic tissues. Cancer Res. 1974; 34: 2814–2822
   PubMed Web of Science ®Google Scholar
• Tamargo R. J., Myseros J. S., Epstein J. I., Yang M. B., Chasin M., Brem H. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery to the brain. Cancer Res. 1993; 53: 329–333
   PubMed Web of Science ®Google Scholar
• Tan J. S., Butterfield D. E., Voycheck C. L., Caldwell K. D., Li J. T. Surface modification of nanoparticles by PEO/PPO block copolymers to minimise interactions with blood components and prolong blood circulation in rats. Biomaterials 1993; 14: 823–833
   PubMed Web of Science ®Google Scholar
• Thomas G. D., Chappel M. J., Dykes P. W., Ramsden D. B. Effect of dose, molecular size, affinity and protein binding on tumor uptake of antibody or ligand. A biomathematical model. Cancer Res. 1989; 49: 3290–3296
   PubMed Web of Science ®Google Scholar
• Toole B. P., Biswas C., Gross J. Hyaluronate and invasiveness of V2 carcinoma. Proc. Natl. Acad. Sci. USA 1979; 76: 6299–6303
   PubMed Web of Science ®Google Scholar
• Trail R. A., Willner D., Lasch S. J., Henderson A. J., Hofstead S., Casazza A. M., Firestone R. A., Hellstrom I., Hellstrom K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212–215
   PubMed Web of Science ®Google Scholar
• Vitetta E. S. Immunotoxins: Magic bullets or misguided missiles?. Trends Pharmacol. Sci. 1993; 14: 148–154
   PubMed Web of Science ®Google Scholar
• Wada R., Hyon S. H., Ikada Y., Nakao Y., Yoshikawa H., Muranishi S. Lactic acid oligomer microspheres containing an anticancer agent for selective lymphatic delivery: I. In vitro studies. J. Bioactive Compat. Polym. 1988; 3: 126–136
   Google Scholar
• Walter K. A., Cahan M. A., Gur A., Tyler B., Hilton J., Colvin O. M., Burger P. C., Domb A., Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994; 54: 2207–2212
   PubMed Web of Science ®Google Scholar
• Weinstein J. N., Eger R. R., Covell D. G., Black C. D. The pharmacology of monoclonal antibodies. Ann. N.Y Acad. Sci. 1987; 507: 199–210
   PubMed Web of Science ®Google Scholar
• Williams B. Soluble medicated hydroxypropyl cellulose cartridge. U.S. Patent 1982; 4: 317–447
   Google Scholar
• Winter G., Harris W. J. Humanized antibodies. Trends Pharmacol. Sci. 1993; 14: 139–142
   PubMed Web of Science ®Google Scholar
• Yazdi P, Murphy R. Quantitative analysis of protein synthesis inhibition by transferrin–toxin conjugates. Cancer Res. 1994; 54: 6387–6394
   PubMed Web of Science ®Google Scholar
• Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Shibazaki C., Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991; 51: 3229–3336
   PubMed Web of Science ®Google Scholar
• Yuan F., Leunig M., Huang S. K., Berk D. A., Papahadjopoulas D., Jain R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994a; 54: 3352–3356
   PubMed Web of Science ®Google Scholar
• Yuan F., Salehi H. A., Boucher Y., Vasthere U. S., Tuma R. F., Jain R. K. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994b; 54: 4564–4568
   PubMed Web of Science ®Google Scholar